Gastro Flashcards
Pattern of LFTs in non-alcoholic steatohepatitis
ALT > AST
NASH - US findings
Increased echogenicity
Pellagra features
4 Ds:
- dementia
- dermatitis
- diarrhoea
- death
Pellagra = deficiency of
Vitamin B3 (Niacin)
Small bowel bacterial overgrowth (SBBOS) - gold standard diagnostic investigation
Jejunal aspirate - showing >100,000 bacteria/ml
Hydatid cyst (tapeworm Echinococcus)- clinical features
Cyst in liver or lungs
Type 1 hypersensitivity reaction if leaks
Biliary rupture (colic, jaundice + urticaria)
Whipple’s disease - infective agent
Tropheryma whippelii
Whipple’s disease - features
Insidious: Malabsorption Arthralgia Lymphadenopathy Cognitive impairment
Whipple’s disease - diagnosis
Jejunal biopsy - shows macrophages containing Periodic acid-Schiff (PAS) granules
Patients with ascites, give antibiotic prophylaxis for SBP if:
Had an episode of SBP previously
or
Ascitic fluid protein <15g/l + Child-Pugh score >9 or hepatorenal syndrome
Antibiotic prophylaxis for SBP
PO ciprofloxacin / norfloxacin
Blatchford score - Urea 6.5 - 8
2
Blatchford score - Urea 8 - 10
3
Blatchford score - Urea 10 - 25
4
Blatchford score - Urea >25
6
Blatchford score - Hb 12 - 13 (Man)
1
Blatchford score - Hb 10 - 12 (Man)
3
Blatchford score - Hb < 10 (Man)
6
Blatchford score - Hb 10 - 12 (Woman)
1
Blatchford score - Hb < 10 (Woman)
6
Blatchford score - Systolic BP 100 - 109
1
Blatchford score - Systolic BP 90 - 99
2
Blatchford score - Systolic BP < 90
3
Blatchford score - other markers scoring 1
Pulse >= 100
Presents with malaena
Blatchford score - other markers scoring 2
Presents with syncope
Hepatic disease
Cardiac failure
Treatment of bile acid diarrhoea (BAD)
Bile acid sequestrants - cholestyramine
Diagnosis of bile acid malabsorption
SeHCAT (selenium homocholic acid taurine) scan shows <15% retention at 7 days
H. pylori eradication - no allergies
7 days of
PPI + amoxicillin + clarithromycin/metronidazole
H. pylori eradication - penicillin allergic
PPI + clarithromycin + metronidazole
H. pylori eradication - penicillin allergic and previous clarithromycin use
PPI + bismuth + metronidazole + tetracycline
Patient with cirrhosis - first scope shows no varices
Rescope 2-3 years
Patient with cirrhosis - scope shows Grade 1 varices
Rescope 1 year
Patient with cirrhosis - scope shows grade 2 or 3 varices, or signs of bleeding
Non-cardio selective beta blocker
Crohns management - what does combined immunomodulator + biological therapy increase risk for
Non-melanoma skin cancer
Hepatosplenic T-cell lymphoma
Causes of ascites with SAAG > 11g/L
Liver (failure, mets)
Cardiac
Budd-Chiari
Portal vein thrombosis
Causes of ascites with SAAG < 11g/L
non-portal HTN
Hypoalbuminemia (nephrotic syndrome, malnutrition)
Malignancy
TB
Pancreatitis, bowel obstruction
Wilsons disease - clinical features
Deranged LFTs
Movement disorder
Psychiatric disturbance
Definition SBP
Ascites neutrophil count > 250 cells / mm^3
UC patient with increased stool frequency, incontinence after ileal pouch-anal anastamosis
Pouchitis
1st line management of pouchitis
Metronidazole or ciprofloxacin
Colonoscopy shows normal appearance, but colonic biopsy shows lymphocytic infiltrate
Microscopic colitis (chronic inflammatory)
Risk factors for microscopic colitis
SSRIs
NSAIDs
PPIs
Smoking
IBS constipation, despite optimal laxatives - next step
Linaclotide (guanylate cyclase-C receptor agonist)
C.diff 1st line treatment
PO Metronidazole 10 - 14 days
C.diff - 2nd line or severe
PO Vancomycin
C.diff - not responding to 1st or 2nd line treatment
Fidaxomicin
C.diff - life-threatening
PO Vancomycin + IV Metronidazole
Gardner’s syndrome (variant of familial adenomatous polyposis) presents with
Osteomas of the skull/jaw
Features of Alkaptonuria (ochronosis) AR disorder
Pigmented sclera
Urine turns black in air
Renal stones
Intervertebral disc calcification
Significance of HbsAg (Hepatitis B surface antigen)
Implies acute disease (usually present 1-6m)
If present >6m implies chronic disease
Significance of HbsAb (Hepatitis B surface antibody)
Immune
(either through exposure or immunisation)
Not present in chronic disease
Significance of HBcAb (Hepatitis B core antibody)
Previous (or current) infection
IgM present for ~6 months
IgG persists
Significance of HbeAg (Hepatitis B envelope antigen)
Marker of infectivity (breakdown of infected liver cells)
Hepatitis B serology seen in previous immunisation
anti-HBs only
Hepatitis B serology seen in previous infection >6 months ago + not a carrier
anti-HBc positive
HBsAg negative
Hepatitis B serology seen in previous infection, now a carrier
anti-HBc positive
HBsAg positive
Budd-Chiari - triad
Sudden onset abdominal pain
Ascites
Tender hepatosplenomegaly
Features of haemochromatosis
Bronzed Diabetes Arthritis/pseudogout Liver cirrhosis Cardiomyopathy Impotence
Haemochromatosis + joint pain
pseudogout
Ulcerative colitis - Inducing remission in mild-moderate proctitis - 1st line
Rectal aminosalicylate
Ulcerative colitis - Inducing remission in mild-moderate proctitis - 2nd line
Add oral aminosalicylate
Ulcerative colitis - Inducing remission in mild-moderate proctitis - 3rd line
Add topical or oral corticosteroid
Medications which cause false positive 5-HIAA urinary collection results
Paracetamol
Naproxen
Caffeine
Fluorouracil
Medications which cause false negative 5-HIAA urinary collection results
Aspirin
Levodopa
Methyldopa
ACTH
Foods which cause false positive 5-HIAA urinary collection results
Banana Avocado Aubergine Pineapple Plums Walnuts Tomatoes
Antibodies seen in Type I Autoimmune Hepatitis
Anti-nuclear antibodies (ANA)
+/-
Anti-smooth muscle antibodies (SMA)
Antibodies seen in Type II Autoimmune Hepatitis
Anti-liver/kidney microsomal type 1 antibodies (LKM1)
Antibodies seen in Type III Autoimmune Hepatitis
Soluble liver-kidney antigen
Examples of aminosalicylate drugs
5-ASA
Sulphasalazine
Mesalazine
Olsalazine
Sulphasalazine - side effects
Heinz body anaemia Megaloblastic anaemia Fibrosis Oligospermia Rash Agranulocytosis
Mesalazine - side effects
Pancreatitis
Agranulocytosis
GI upset
Crohns flare - 1st line for inducing remission
Glucocorticoid (hydrocortisone, prednisolone) oral, topical or IV
Crohn’s flare - 2nd line options
5-ASAs (eg mesalazine)
Azathioprine or mercaptopurine as an adjunct
Infliximab
Drugs which case a hepatocellular liver injury
Paracetamol Nitrofurantoin Sodium valproate, phenytoin Statins Amiodarone Anti-TBs
Drugs which cause a cholestatic liver disease
Co-amoxiclav, Flucloxacillin, Erythromycin
COCP
Sulphonylureas
Fibrates
Drugs which cause liver cirrhosis
Methotrexate
Amiodarone
Methyldopa
Colonoscopy - 1-2 small (<1cm) adenomas
Low risk - No follow up, or, 5 yearly until one negative scope
Colonoscopy - 3-4 small (<1cm) adenomas
Intermediate risk - 3-yearly colonoscopy, until two consecutive negative scopes
Colonoscopy - 1-2 adenomas, one is >1cm
Intermediate risk - 3-yearly colonoscopy, until two consecutive negative scopes
Colonoscopy - 5 or more adenomas
High risk - yearly scope
Colonoscopy - 3 or more adenomas if one is >1cm
High risk - yearly scope
Absolute contraindications for TIPSS
High Child-Pugh score Hepatic encephalopathy Right heart failure Sepsis Biliary obstruction
Test for haemochromatosis (no family history)
Transferrin saturation - >55%
Test for haemochromatosis (with family history)
HFE genotyping
Crohns - biopsy shows
Transmural inflammation with lymphoid aggregates
1st line treatment for Entamoeba histolytica
Metronidazole
Crohns - 1st line for maintaining remission
Azathioprine or mercaptopurine
Primary biliary cirrhosis - associated conditions
Sjogren’s (80%)
RA
Systemic sclerosis
Thyroid disease
Primary biliary cirrhosis - complications
Cirrhosis + portal hypertension
Hepatocellular carcinoma
Osteomalacia + osteoporosis
Antibodies in PBC
AMA (anti-mitochondrial) M2 subtype - 98%
Smooth muscle - 30%
Raised serum IgM
Features of scurvy
Perifollicular bleeding Easy bruising Gingivitis Sjogren's Arthralgia
Zieve syndrome - triad
Haemolytic anemia
Cholestatic jaundice
Transient hyperlipidemia
IBD and colorectal cancer screening - what counts as ‘Lower risk’ (5-yearly)
Extensive colitis but no inflammation
Left-sided colitis
Crohn’s colitis <50% colon
IBD and colorectal cancer screening - what counts as ‘Intermediate risk’ (3-yearly)
Extensive colitis with mild inflammation
Post-inflammatory polyps
FH of colorectal Ca in 1st-degree relative (>50yo)
IBD and colorectal cancer screening - what counts as ‘Higher risk’ (Yearly)
Extensive colitis with mod/severe inflammation
Stricture in past 5 years
Dysplasia in past 5 years, declining surgery
PSC
FH of colorectal Ca in 1-degree relative <50yo
Management of acute alcoholic hepatitis
Prednisolone, pabrinex, nutritional support
Small bowel bacterial overgrowth syndrome - 1st line investigation
Hydrogen breath test
Risk factors for SBBOS
Scleroderma
Congenital GI abnormality (neonates)
Diabetes
Barrett’s oesophagus - follow up following eradication of low-grade dysplasia
Endoscopy every 6 months for first year, annually thereafter
Barrett’s oesophagus - follow up following eradication of high-grade dysplasia
Endoscopy every 3 months for first year, every 6 months for second year, annually thereafter
Barrett’s oesophagus - follow up if metaplasia (no dysplasia)
Endoscopy every 3-5 years
Pregnant and on azathioprine for IBD/arthritis/skin disease
Continue Azathioprine
UGI bleed - criteria for red cell transfusion
Hb <70
or Hb 70-80 and actively bleeding/haemodynamically unstable
UGI bleed - criteria for platelet transfusion
Actively bleeding and platelet count <50
UGI bleed - criteria for FFP
Fibrinogen <1 g/L
or
PT/APTT/INR >1.5 normal value
UGI bleed - criteria for antibiotics
All patients with acute variceal bleed > gram-negative cover (Ceftriaxone)
Signs of acute hepatic decompensation
Asterixis
Jaundice
Hepatic encephalopathy
Constructional apraxia
1st line test for IBD
Faecal calprotectin
Faecal calprotectin is raised in
UC/Crohns Bowel malignancy Coeliac Infectious colitis NSAID use
Blood marker associated with autoimmune pancreatitis
Raised serum IgG4
Monitoring required when starting oral aminosalicylate
FBC and renal function: before, at 3 months, annually thereafter
5-year survival rate of: Duke’s A bowel cancer (confined to mucosa and submucosa)
95% in men
100% in women
5-year survival rate of: Duke’s B bowel cancer (extends through muscularis propria)
> 80% in men
90% in women
5-year survival rate of: Duke’s C bowel cancer (regional lymph nodes involved)
65% in men
65% in women
5-year survival rate of: Duke’s D bowel cancer (distant spread)
> 5% in men
10% in women
Gastric cancer - suitable for Endomucosal resection if:
Confined to mucosa
Less than 2 cm diameter
Low/moderate differentiation
No ulceration/lymphovascular involvement
Gastric cancer - treatment for stage II and III carcinoma
Neoadjuvant chemotherapy, prior to radical surgery
HbA1c target for diabetes related to pancreatic resection
53
Frequency of bowel screening colonoscopy in patients with both Crohns and PSC
Annual
Management of hereditary haemochromatosis
Phlebotomy indicated for all patients with initial ferritin >1000 mcg/L
Aim for 50-100mcg/L
After lactulose, which other medications can be used to treat hepatic encephalopathy
Rifaximin
Other antibiotics
Lysosomal storage disorder which features ‘cherry red spot’ macula
Tay Sachs
Lysosomal storage disorder which causes massive splenomegaly
Gaucher’s
Glycogen storage disorder which causes cardiomyopathy
Pompe’s disease
Glycogen storage disorder with rhabdomyolysis after exercise/lactic acidaemia
McArdle’s
Glycogen storage disorder causing hypoglycaemia + hepatomegaly
Von Gierke